Early treatment-related neutropenia predicts response to palbociclib

BACKGROUND: Palbociclib is highly active in oestrogen-receptor positive (ER+) metastatic breast cancer, but neutropenia is dose limiting. The goal of this study was to determine whether early neutropenia is associated with disease response to single-agent palbociclib. METHODS: Blood count and diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: McAndrew, Nicholas P., Dickson, Mark A., Clark, Amy S., Troxel, Andrea B., O’Hara, Mark H., Colameco, Christopher, Gallager, Maryann, Gramlich, Kristi, Zafman, Kelly, Vaughn, David, Schwartz, Gary K., O’Dwyer, Peter J., DeMichele, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492243/
https://www.ncbi.nlm.nih.gov/pubmed/32641862
http://dx.doi.org/10.1038/s41416-020-0967-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492243/
https://www.ncbi.nlm.nih.gov/pubmed/32641862
http://dx.doi.org/10.1038/s41416-020-0967-7

Ejemplares similares